Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus
BACKGROUND. Type 2 diabetes mellitus (T2DM) is an independent risk factor for adverse clinical outcomes in patients with Covid-19. There is currently insufficient data evaluating the efficacy and safety of drugs for the treatment of COVID-19, especially in patients with T2DM.AIM. The aim of study wa...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2021-09-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/12764 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849729789427974144 |
|---|---|
| author | K. G. Lobanova T. Y. Demidova S. N. Perekhodov M. B. Antsiferov |
| author_facet | K. G. Lobanova T. Y. Demidova S. N. Perekhodov M. B. Antsiferov |
| author_sort | K. G. Lobanova |
| collection | DOAJ |
| description | BACKGROUND. Type 2 diabetes mellitus (T2DM) is an independent risk factor for adverse clinical outcomes in patients with Covid-19. There is currently insufficient data evaluating the efficacy and safety of drugs for the treatment of COVID-19, especially in patients with T2DM.AIM. The aim of study was to identify an associative relationship between the drugs used and the clinical outcomes of patients with Covid-19 and T2DM.MATERIALS AND METHODS. A retrospective analysis of the clinical outcomes of 1753 patients with COVID-19 who were hospitalized to the redesignated departments of multidisciplinary city clinical hospital in the period from 23.03.2020 to 01.06.2020.RESULTS. The total number of patients is 1,753, of which 311 (17.7%) are patients with DM2. 92.6% of patients received treatment for COVID-19. At the same time, 91.4% of patients received antibiotics (a/b), 61.5% — bronchodilators, 56.6% — injectable anticoagulants (a/c), 45.2% — hydroxychloroquine, 6.3% — antiviral drugs, 5.4% — oral a/c, 4.6% — glucocorticosteroids (GCS), 1.9% — Tocilizumab.Decrease of risk of death among patients with COVID-19 was as the therapy of a/b (OR 0.07, 95% CI 0.05–0.11, p<0.05), bronchodilators (OR 0.12, 95% CI 0.08–0.18, p<0.05) and injection a/c (OR 0.47, 95% CI 0.34–0.67, p<0.05). At the same time, among patients with DM2, compared with patients without DM2, there was a more pronounced reduction in the risk of death during injectable a/c therapy: among patients with DM2, the risk of death decreased by 2.6 times (OR 0.39, 95% CI 0.21–0.73, p<0.05), among patients without DM2 — by 2.1 times (OR 0.47, 95% CI 0.31–0.71, p<0.05). Antiviral drugs was associated with an increased chance of death among patients without DM2 (OR 2.64, 95% CI 1.44–4.86, p<0.05) and among patients with DM2 (OR 4.98, 95% CI 2.11–11.75, p<0.05).CONCLUSION. A significant decrease of the risk of death among patients with COVID-19 was as the therapy of a/b, bronchodilators, and injectable a/c. An increase of the risk of death was observed during therapy with antiviral drugs. |
| format | Article |
| id | doaj-art-29d10e5a50dc4997bfee9c462bc4d108 |
| institution | DOAJ |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2021-09-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-29d10e5a50dc4997bfee9c462bc4d1082025-08-20T03:09:04ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782021-09-0124323124210.14341/DM1276410887Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitusK. G. Lobanova0T. Y. Demidova1S. N. Perekhodov2M. B. Antsiferov3Pirogov Russian National Research Medical UniversityPirogov Russian National Research Medical UniversityDemikhov City Clinical HospitalEndocrinological Dispensary of the Moscow City Health DepartmentBACKGROUND. Type 2 diabetes mellitus (T2DM) is an independent risk factor for adverse clinical outcomes in patients with Covid-19. There is currently insufficient data evaluating the efficacy and safety of drugs for the treatment of COVID-19, especially in patients with T2DM.AIM. The aim of study was to identify an associative relationship between the drugs used and the clinical outcomes of patients with Covid-19 and T2DM.MATERIALS AND METHODS. A retrospective analysis of the clinical outcomes of 1753 patients with COVID-19 who were hospitalized to the redesignated departments of multidisciplinary city clinical hospital in the period from 23.03.2020 to 01.06.2020.RESULTS. The total number of patients is 1,753, of which 311 (17.7%) are patients with DM2. 92.6% of patients received treatment for COVID-19. At the same time, 91.4% of patients received antibiotics (a/b), 61.5% — bronchodilators, 56.6% — injectable anticoagulants (a/c), 45.2% — hydroxychloroquine, 6.3% — antiviral drugs, 5.4% — oral a/c, 4.6% — glucocorticosteroids (GCS), 1.9% — Tocilizumab.Decrease of risk of death among patients with COVID-19 was as the therapy of a/b (OR 0.07, 95% CI 0.05–0.11, p<0.05), bronchodilators (OR 0.12, 95% CI 0.08–0.18, p<0.05) and injection a/c (OR 0.47, 95% CI 0.34–0.67, p<0.05). At the same time, among patients with DM2, compared with patients without DM2, there was a more pronounced reduction in the risk of death during injectable a/c therapy: among patients with DM2, the risk of death decreased by 2.6 times (OR 0.39, 95% CI 0.21–0.73, p<0.05), among patients without DM2 — by 2.1 times (OR 0.47, 95% CI 0.31–0.71, p<0.05). Antiviral drugs was associated with an increased chance of death among patients without DM2 (OR 2.64, 95% CI 1.44–4.86, p<0.05) and among patients with DM2 (OR 4.98, 95% CI 2.11–11.75, p<0.05).CONCLUSION. A significant decrease of the risk of death among patients with COVID-19 was as the therapy of a/b, bronchodilators, and injectable a/c. An increase of the risk of death was observed during therapy with antiviral drugs.https://www.dia-endojournals.ru/jour/article/view/12764covid-19type 2 diabetes mellitushydroxychloroquineantibacterial therapyantiviral therapytocilizumabanticoagulant therapymortality |
| spellingShingle | K. G. Lobanova T. Y. Demidova S. N. Perekhodov M. B. Antsiferov Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus Сахарный диабет covid-19 type 2 diabetes mellitus hydroxychloroquine antibacterial therapy antiviral therapy tocilizumab anticoagulant therapy mortality |
| title | Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus |
| title_full | Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus |
| title_fullStr | Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus |
| title_full_unstemmed | Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus |
| title_short | Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus |
| title_sort | clinical characteristics of patients with covid 19 depending on the treatment received and the presence of type 2 diabetes mellitus |
| topic | covid-19 type 2 diabetes mellitus hydroxychloroquine antibacterial therapy antiviral therapy tocilizumab anticoagulant therapy mortality |
| url | https://www.dia-endojournals.ru/jour/article/view/12764 |
| work_keys_str_mv | AT kglobanova clinicalcharacteristicsofpatientswithcovid19dependingonthetreatmentreceivedandthepresenceoftype2diabetesmellitus AT tydemidova clinicalcharacteristicsofpatientswithcovid19dependingonthetreatmentreceivedandthepresenceoftype2diabetesmellitus AT snperekhodov clinicalcharacteristicsofpatientswithcovid19dependingonthetreatmentreceivedandthepresenceoftype2diabetesmellitus AT mbantsiferov clinicalcharacteristicsofpatientswithcovid19dependingonthetreatmentreceivedandthepresenceoftype2diabetesmellitus |